GenesisCare has appointed its first Global Chief Medical Officer, Walter J. (Wally) Curran, Jr, MD, FACR, FASCO. This appointment follows the recent acquisition of integrated cancer care provider 21st Century Oncology, increasing access to advanced cancer care for patients in more than 290 locations across the United States. The appointment is a pivotal step in achieving the organization’s mission to ensure that as many cancer patients as possible receive the right outcome at the right time, close to home.
Walter J. (Wally) Curran, Jr, MD, FACR, FASCO
With Dr. Curran’s appointment, GenesisCare is committed to expanding its research and clinical trial programs and enhancing patients’ access to evidence-based cancer care. Through such research, GenesisCare noted a 10% increase in patients in the United States presenting with late-stage cancer in 2020. Many in the medical community attribute this to the delays in detection and treatment due to the COVID pandemic. GenesisCare reaffirms its commitment to bringing access to the latest treatment technology, specialists, clinical research, and facilities to its local communities in 440 locations across the globe.
“We are delighted to welcome Dr. Curran as the new Global Chief Medical Officer of GenesisCare. Wally is a highly respected and world-renowned expert and innovator in oncology. He is also driven by the same mission as GenesisCare, to increase access to the highest quality of cancer care so our patients can achieve their best possible life outcomes,” said Dan Collins, Founder and Global Chief Executive Officer of GenesisCare.
Looking Forward
Dr. Curran currently serves as Executive Director of the Winship Cancer Institute of Emory University and Georgia Research Alliance Eminent Scholar and Chair in Cancer Research, the Lawrence W. Davis Professor and Chairman of Emory’s Department of Radiation Oncology, and Group Chairman of NRG Oncology, a National Cancer Institute–funded national cancer clinical trials cooperative group. Dr. Curran will retain his leadership role in NRG Oncology.
“GenesisCare has a clear purpose and mission to improve patient access and achieve the best possible life outcomes for its patients. I have witnessed firsthand the positive impact GenesisCare is already having on local U.S. communities through its innovative and patient-driven approach to cancer care,” stated Dr. Curran.
“My mission throughout my career has been to put my patients first, challenge the boundaries of cancer care, never stop learning, and never stop aligning research with care and understanding our technological possibilities,” he said. “GenesisCare is at the forefront of marrying the best clinical care practices with the most advanced technologies, methodologies, and research. I am honored and excited to join the team.”
Interim Executive Director Appointed by Winship Cancer Institute
Adam Marcus, PhD, has been appointed Interim Executive Director of Winship Cancer Institute of Emory University, assuming Dr. Curran’s role while Emory University conducts a national search for the institution’s next Executive Director. An advisory committee, with representation from across the Woodruff Health Sciences Center including Winship leaders, has been launched to oversee the Executive Director search.
Adam Marcus, PhD
Dr. Marcus, a member of Winship’s executive leadership team and a fellow of the Woodruff Leadership Academy, serves as the Associate Director for Basic Research and Shared Resources at Winship. He is Professor of Hematology and Medical Oncology and holds the Winship 5K Professorship. Dr. Marcus is also Scientific Director of the Emory Integrated Cellular Imaging Core, one of the Emory Integrated Core Facilities.
Combining Research, Care, and Prevention
As Interim Executive Director, Dr. Marcus will lead a team of Winship senior leaders to advance Winship’s mission to lessen the burden of cancer for the citizens of Georgia through aligning outstanding cancer research and education with its significant cancer prevention and care efforts.
“It is an honor to serve as Interim Executive Director and support Winship’s exceptional teams as we continue to drive innovative research, clinical care, and education,” said Dr. Marcus. “Winship has experienced remarkable achievements under Dr. Curran’s leadership, and I am excited to lead the center during this next phase of growth.”
Dr. Marcus’ research focuses on cancer metastasis, drug development, and image-guided genomics, and he has been continuously funded by the National Institutes of Health (NIH) since joining the Emory faculty in 2006. He is a principal investigator (PI) of five active NIH grants, including a multi-PI R25 Science Education Partnership Award that supports Citizen Science HD. Dr. Marcus co-leads Citizen Science HD, an outreach program that provides opportunities for underrepresented learners in science, technology, engineering, and mathematics.
